Skip to main content
NVDA-2.40%AAPL+2.07%GOOGL+0.03%MSFT-0.04%AMZN+0.20%TSM-0.79%SPCX+2.01%AVGO+0.19%META+0.24%TSLA-0.36%SKHY-3.59%MU-3.98%BRK-B-0.16%LLY+0.62%JPM-0.48%AMD-2.20%WMT+0.12%V-0.23%XOM-0.14%ASMLa-1.48%JNJ-0.16%INTC-3.83%MA-0.51%0700.HK-1.94%ORCL-1.80%1398.HK+0.79%BAC-0.50%ABBV+0.44%CSCO-0.50%CVX-0.61%COST-0.10%LRCX-3.48%KO+0.82%CAT-0.87%AMAT-2.00%0005.HK-0.78%AP2d-1.26%UNH-0.75%DELL-2.68%HSBA.L-1.05%MS-0.15%PG-0.26%GE+0.09%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.20%HD-0.98%GS-0.32%0939.HK+1.66%NZDJPY-2.69%AUDJPY-1.94%CHFJPY-1.66%USDJPY-1.50%GBPJPY-1.39%EURNZD+1.38%EURJPY-1.36%CADJPY-1.36%NZDCAD-1.35%GBPNZD+1.31%NZDUSD-1.23%NZDCHF-1.06%USDNOK+0.94%EURNOK+0.90%CHFNOK+0.82%AUDNZD+0.78%NOKJPY-0.70%USDZAR+0.69%USDSEK+0.67%EURZAR+0.65%EURSEK+0.63%AUDDKK-0.62%AUDCAD-0.61%EURAUD+0.59%GBPZAR+0.55%CHFSEK+0.55%GBPAUD+0.53%AUDSGD-0.50%AUDUSD-0.45%USDMXN+0.43%GBPTRY+0.41%USDTHB+0.41%NZDSGD-0.34%GBPHKD+0.32%EURCHF+0.29%AUDNOK+0.29%GBPMXN-0.28%CADCHF+0.28%AUDCHF-0.28%GBPCHF+0.25%USDPLN+0.23%EURPLN+0.19%USDCHF+0.17%USDILS+0.16%USDSGD+0.15%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%USDTRY+0.11%GBPUSD+0.10%EURCZK-0.10%NZDMXN-0.09%SGDJPY+0.08%USDCNH+0.05%EURGBP+0.05%EURHKD-0.05%GBPCAD-0.05%USDCOP-0.04%EURCNH+0.04%CHFSGD+0.04%USDDKK+0.03%GBPSGD+0.02%PLNJPY+0.01%USDHKD+0.01%EURDKK0.00%EURCAD0.00%XPTUSD-4.76%HG1-4.48%GAGUSD-4.14%XAGUSD-4.14%UKOIL+3.50%USOIL+3.10%SUGAR+1.64%GAUUSD-0.92%XAUUSD-0.92%COTTON+0.71%S1+0.63%COFFEE-0.56%BTCUSD-1.22%ETHUSD-1.04%USDTUSD-0.02%XRPUSD-2.61%SOLUSD-1.44%TRXUSDT0.00%ZECUSDT-5.72%DOGEUSD-2.86%XMRUSDT-1.69%LINKUSD-1.08%XLMUSD-1.94%BCHUSDT-10.58%LTCUSD-1.72%UNIUSD-3.41%TONUSD+24.88%HBARUSDT-1.87%SUIUSD-3.40%TAOUSDT-5.14%AAVEUSD-2.85%DOTUSDT-3.61%ICPUSDT-0.90%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.41%ARBUSDT+1.37%JUPUSDT-2.96%INJUSDT-4.87%STXUSDT-3.07%FETUSDT-3.62%TIAUSDT-0.87%PYTHUSDT-0.07%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.89%OPUSDT-3.00%IOTAUSDT-3.86%POLUSDT-5.76%AXSUSDT-2.47%FARTCOINUSDT-2.74%EOSUSDT-0.68%DYDXUSDT-0.71%ORDIUSDT-0.85%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.40%AAPL+2.07%GOOGL+0.03%MSFT-0.04%AMZN+0.20%TSM-0.79%SPCX+2.01%AVGO+0.19%META+0.24%TSLA-0.36%SKHY-3.59%MU-3.98%BRK-B-0.16%LLY+0.62%JPM-0.48%AMD-2.20%WMT+0.12%V-0.23%XOM-0.14%ASMLa-1.48%JNJ-0.16%INTC-3.83%MA-0.51%0700.HK-1.94%ORCL-1.80%1398.HK+0.79%BAC-0.50%ABBV+0.44%CSCO-0.50%CVX-0.61%COST-0.10%LRCX-3.48%KO+0.82%CAT-0.87%AMAT-2.00%0005.HK-0.78%AP2d-1.26%UNH-0.75%DELL-2.68%HSBA.L-1.05%MS-0.15%PG-0.26%GE+0.09%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.20%HD-0.98%GS-0.32%0939.HK+1.66%NZDJPY-2.69%AUDJPY-1.94%CHFJPY-1.66%USDJPY-1.50%GBPJPY-1.39%EURNZD+1.38%EURJPY-1.36%CADJPY-1.36%NZDCAD-1.35%GBPNZD+1.31%NZDUSD-1.23%NZDCHF-1.06%USDNOK+0.94%EURNOK+0.90%CHFNOK+0.82%AUDNZD+0.78%NOKJPY-0.70%USDZAR+0.69%USDSEK+0.67%EURZAR+0.65%EURSEK+0.63%AUDDKK-0.62%AUDCAD-0.61%EURAUD+0.59%GBPZAR+0.55%CHFSEK+0.55%GBPAUD+0.53%AUDSGD-0.50%AUDUSD-0.45%USDMXN+0.43%GBPTRY+0.41%USDTHB+0.41%NZDSGD-0.34%GBPHKD+0.32%EURCHF+0.29%AUDNOK+0.29%GBPMXN-0.28%CADCHF+0.28%AUDCHF-0.28%GBPCHF+0.25%USDPLN+0.23%EURPLN+0.19%USDCHF+0.17%USDILS+0.16%USDSGD+0.15%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%USDTRY+0.11%GBPUSD+0.10%EURCZK-0.10%NZDMXN-0.09%SGDJPY+0.08%USDCNH+0.05%EURGBP+0.05%EURHKD-0.05%GBPCAD-0.05%USDCOP-0.04%EURCNH+0.04%CHFSGD+0.04%USDDKK+0.03%GBPSGD+0.02%PLNJPY+0.01%USDHKD+0.01%EURDKK0.00%EURCAD0.00%XPTUSD-4.76%HG1-4.48%GAGUSD-4.14%XAGUSD-4.14%UKOIL+3.50%USOIL+3.10%SUGAR+1.64%GAUUSD-0.92%XAUUSD-0.92%COTTON+0.71%S1+0.63%COFFEE-0.56%BTCUSD-1.22%ETHUSD-1.04%USDTUSD-0.02%XRPUSD-2.61%SOLUSD-1.44%TRXUSDT0.00%ZECUSDT-5.72%DOGEUSD-2.86%XMRUSDT-1.69%LINKUSD-1.08%XLMUSD-1.94%BCHUSDT-10.58%LTCUSD-1.72%UNIUSD-3.41%TONUSD+24.88%HBARUSDT-1.87%SUIUSD-3.40%TAOUSDT-5.14%AAVEUSD-2.85%DOTUSDT-3.61%ICPUSDT-0.90%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.41%ARBUSDT+1.37%JUPUSDT-2.96%INJUSDT-4.87%STXUSDT-3.07%FETUSDT-3.62%TIAUSDT-0.87%PYTHUSDT-0.07%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.89%OPUSDT-3.00%IOTAUSDT-3.86%POLUSDT-5.76%AXSUSDT-2.47%FARTCOINUSDT-2.74%EOSUSDT-0.68%DYDXUSDT-0.71%ORDIUSDT-0.85%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%
BL

Bio-Rad Laboratories, Inc. (BIO)

NYSE • Healthcare

$376.97
-$3.14 (-0.8%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$380
Previous Close$376.97
Day Range$373.34 - $380.06
Avg. Volume (3M)233.3K
Market Cap$10.1B
P/E Ratio45.3
52 Week Range
$236.73$396.23
Next EarningsIn 49 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$651M100%
Gross Profitminus cost of goods$345.8M53%
Operating Incomeminus R&D and overhead$72.6M11%
Net Incomeminus taxes and the rest$371.4M57%

In plain terms: out of every $100 in revenue, Bio-Rad Laboratories, Inc. keeps $57 as net profit.

Fundamentals & Financials

Revenue (TTM)
$2.5B
Net Income (TTM)
$222.4M
EPS (TTM)
$8.33
ROA (TTM)
2.17%
Current Ratio
3.14
Dividend Yield
0.2%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-2.3%Q1 2026$2.51
-4.1%Q2 2026$1.89
+49.7%Q3 2026$2.62
Next

Oct 29

in 49 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +49.7%

Bio-Rad Laboratories beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 4, with adjusted EPS of $2.62 topping the $1.75 estimate by about +49.7% and revenue of about $651.0 million exceeding the $624.0 million consensus by +4.3%. Revenue slipped 0.1% from $651.6 million a year ago, while adjusted EPS edged up 0.4% from $2.61. Gross profit came to about $345.8 million, leaving gross margin near 53%, and operating income was about $72.6 million with operating margin around 11%. Operating cash flow reached $98.7 million; Bio-Rad also repurchased $31.5 million of stock and paid $15.7 million in dividends. Consensus for the next period calls for EPS of $2.38 on revenue of $651.1 million.

View full earnings history

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops and sells life-science and clinical diagnostics products on the NYSE under BIO, operating in healthcare as a maker of laboratory and diagnostic systems. Across its two businesses, the company generated $2.6 billion of revenue in FY2025.

Name
Bio-Rad Laboratories, Inc.
CEO
Norman D. Schwartz
Website
www.bio-rad.com
Industry
Healthcare
Year Founded
1952
Employees
7,450

Today's Snapshot

AI-generated

BIO opened 1.3% higher at 382.01, while its sector was flat. Bio-Rad Laboratories said it aims to reach 20% operating margins.

Trading Volume

Below 10d avg (191.0K)

38.9K

vs S&P 500 Today

Inline with Market

+0.02%

Updated: September 10, 2026 at 14:58 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
BIO posts a buy stance driven by a strong trend reading (ADX near 49) and price positioned above medium and longer-term averages even though the stock sits below very short-term moving averages. Momentum and MACD are mixed: MACD is positive but short-term momentum is soft, and RSI is neutral, so the advance appears trend-driven rather than impulsive. Volatility is moderate with an ATR near $11 and on-balance volume is not confirming recent strength, leaving some divergence between trend and volume. Technical takeaway: Buy — underlying trend strength and supportive medium/long averages outweigh short-term pullback.
All signals
  • EMA (5 indicators)$314.19 - $380.13
    Buy
  • RSI (14)55.10
    Neutral
  • Stochastic %K (14, 3, 3)41.15
    Neutral
  • MACD Level (12, 26)11.03
    Neutral

Peers & Related Assets

CRLCharles River Laboratories International, Inc.
$278.35-0.9%
PENPenumbra, Inc.
$319.57+0.1%
DVADaVita Inc.
$181.29-0.9%
ALGNAlign Technology, Inc.
$150.17-1.8%
GMEDGlobus Medical, Inc.
$74.52-0.7%
HSICHenry Schein, Inc.
$87.97-1.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.